摘要
目的:观察病毒性肺炎方治疗新型冠状病毒感染的临床效果。方法:将65例确诊新型冠状病毒奥密克戎毒株感染患者分为病毒性肺炎方治疗组和中医辨证治疗组,其中病毒性肺炎方治疗组34例,中医辨证治疗组31例。中医辨证治疗组参照《新型冠状病毒肺炎诊疗方案(试行第九版)》推荐中药处方分为湿郁肺脾型、湿热蕴毒型、肺脾气虚型3型辨证治疗。治疗中观察两组患者主要症状发热、咳嗽咳痰、咽痛、鼻塞流涕消失时间及鼻咽、口咽拭子新型冠状病毒核酸N基因及OFR基因(连续两次,采样间隔24小时)CT值≥35时间。结果:病毒性肺炎方治疗组在退热,缓解咽痛、鼻塞流涕时间方面与中医辨证治疗组相当,两组比较,差异无统计学意义(P>0.05)。在缓解咳嗽咳痰时间方面,病毒性肺炎方治疗组为(3.7±1.8)天,中医辨证治疗组为(5.2±1.9)天,两组比较P<0.05,t=2.45;病毒核酸N基因及OFR基因CT值≥35时间方面,病毒性肺炎方治疗组为(15.0±5.4)天,中医辨证治疗组为(18.8±7.7)天,两组比较P<0.05,t=2.32,病毒性肺炎方治疗组稍优于中医辨证治疗组,两组差异有统计学意义。结论:病毒性肺炎方治疗新型冠状病毒奥密克戎毒株感染在退热,缓解咽痛、鼻塞流涕方面与辨证治疗相当,缓解咳嗽咳痰及核酸转阴时间方面较辨证治疗有一定优势,具有一定的临床推广价值。
Objective:To observe the clinical effect of Bingduxing Feiyan prescription(病毒性肺炎方)on COVID-19(SARSCoV-2)infection.Methods:A total of 65 patients with confirmed infection of Omicron strain of novel coronavirus were divided into the Bingduxing Feiyan prescription treatment group and the TCM syndrome differentiation treatment group,among which 34 cases were in the Bingduxing Feiyan prescription treatment group and 31 cases were in the TCM syndrome differentiation treatment group.According to the diagnosis and treatment plan of COVID-19(Trial ninth edition),the TCM prescription recommended in the TCM treatment group can be divided into the following three types of syndrome differentiation treatment:dampness-stagnation lung and spleen type,damp-heat toxic type and deficiency of lung and spleen Qi(气)type.During treatment,the disappearance time of main symptoms such as fever,cough,sputum,sore throat,nasal obstruction and runny nose,and the CT value of nucleic acid N gene and OFR gene of 2019-NCoV in nasopharyngeal and oropharyngeal swabs(two consecutive times,sampling interval 24 hours)not less than 35 were observed.Results:The Bingduxing Feiyan prescription treatment group was similar to the TCM syndrome differentiation treatment group in terms of reducing fever,relieving pharyngeal pain,nasal congestion and runny nose,and there was no statistical significance between the two groups(P>0.05).The duration of relieving cough and sputum was(3.7±1.8)days in the Bingduxing Feiyan prescription group and(5.2±1.9)days in the TCM syndrome differentiation treatment group,P<0.05,t=2.45.CT values of viral nucleic acid N gene and OFR gene not less than 35 were(15.0±5.4)days in the Bingduxing Feiyan prescription treatment group and(18.8±7.7)days in the TCM syndrome differentiation treatment group,P<0.05,t=2.32,the Bingduxing Feiyan prescription treatment group was slightly better than the TCM syndrome differentiation treatment group,and the comparison between the two groups was statistically significant.Conclusion:B
作者
张双胜
左万里
范发才
李影捷
胡长征
陈晓东
束明慧
ZHANG Shuangsheng;ZUO Wanli;FAN Facai;LI Yingjie;HU Changzheng;CHEN Xiaodong;SHU Minghui
出处
《中医临床研究》
2023年第12期71-73,共3页
Clinical Journal Of Chinese Medicine
基金
2020年广东省科技专项资金(“大专项+任务清单”)项目计划(第二批)—新型冠状病毒肺炎防控科技攻关专项(江科[2020]182号)。
关键词
新型冠状病毒感染
病毒性肺炎方
中医药疗法
COVID-19
Bingduxing Feiyan prescription
Traditional Chinese medicine therapy
